Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free LIPO Stock Alerts

Lipella Pharmaceuticals (LIPO) Competitors

Lipella Pharmaceuticals logo
$0.04 0.00 (-0.50%)
As of 05/14/2026 03:44 PM Eastern
Compare

LIPO vs. VRAX, BPTH, HEPA, SRNE, and ONCO

Should you buy Lipella Pharmaceuticals stock or one of its competitors? MarketBeat compares Lipella Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipella Pharmaceuticals include Virax Biolabs Group (VRAX), Bio-Path (BPTH), Hepion Pharmaceuticals (HEPA), Sorrento Therapeutics (SRNE), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.

How does Lipella Pharmaceuticals compare to Virax Biolabs Group?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Virax Biolabs Group has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Virax Biolabs Group's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Virax Biolabs Group N/A N/A N/A

Lipella Pharmaceuticals has higher revenue and earnings than Virax Biolabs Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A
Virax Biolabs Group$10K60.76-$6.06MN/AN/A

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lipella Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Virax Biolabs Group has a consensus price target of $1.00, suggesting a potential upside of 614.29%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Virax Biolabs Group had 3 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Virax Biolabs Group and 0 mentions for Lipella Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 1.15 beat Lipella Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Virax Biolabs Group Positive

Summary

Virax Biolabs Group beats Lipella Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Bio-Path?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Lipella Pharmaceuticals has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A
Bio-PathN/AN/A-$16.08M-$1.06N/A

Lipella Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market.

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Bio-Path Neutral

Bio-Path has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Bio-Path N/A -2,842.40%-337.48%

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lipella Pharmaceuticals beats Bio-Path on 8 of the 10 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Hepion Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Lipella Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

Lipella Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Hepion Pharmaceuticals Neutral

Hepion Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Hepion Pharmaceuticals N/A -812.56%-207.31%

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lipella Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Sorrento Therapeutics?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Lipella Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A

Lipella Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Sorrento Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Sorrento Therapeutics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Sorrento Therapeutics N/A N/A N/A

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sorrento Therapeutics beats Lipella Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Onconetix?

Onconetix (NASDAQ:ONCO) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

In the previous week, Onconetix had 5 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 5 mentions for Onconetix and 0 mentions for Lipella Pharmaceuticals. Onconetix's average media sentiment score of 0.72 beat Lipella Pharmaceuticals' score of 0.00 indicating that Onconetix is being referred to more favorably in the media.

Company Overall Sentiment
Onconetix Positive
Lipella Pharmaceuticals Neutral

23.9% of Onconetix shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Onconetix has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Lipella Pharmaceuticals has a net margin of -988.83% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -111.36% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Onconetix-1,316.28% -111.36% -43.77%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

Lipella Pharmaceuticals has lower revenue, but higher earnings than Onconetix. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconetix$810K0.32-$14.03M-$216.73N/A
Lipella Pharmaceuticals$536.36K0.34-$5.02M-$2.42N/A

Summary

Onconetix beats Lipella Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIPO vs. The Competition

Export
MetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$185K$3.42B$6.34B$12.37B
Dividend YieldN/A2.31%2.80%5.35%
P/E Ratio-0.0118.4720.6625.63
Price / Sales0.34294.84542.6376.59
Price / CashN/A125.2943.2656.33
Price / Book0.036.939.936.97
Net Income-$5.02M$24.11M$3.55B$333.62M
7 Day PerformanceN/A5.89%1.70%1.09%
1 Month PerformanceN/A-0.91%0.49%3.08%
1 Year PerformanceN/A74.58%39.41%35.68%

Lipella Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIPO
Lipella Pharmaceuticals
N/A$0.04
-0.5%		N/A-98.3%$185K$536.36KN/A4
VRAX
Virax Biolabs Group
3.2095 of 5 stars		$0.13
+3.5%		$1.00
+693.7%		-87.1%$528K$2.99KN/A5
BPTH
Bio-Path
N/A$0.06
flat		N/A-84.0%$517KN/AN/A10
HEPA
Hepion Pharmaceuticals
N/A$0.04
-16.8%		N/A-21.8%$505KN/AN/A20
SRNE
Sorrento Therapeutics
N/A$0.00
+28.6%		N/A-92.5%$496K$60.32MN/A800

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel